A study looking at everolimus for neuroendocrine tumours of the pancreas (The OBLIQUE study)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Neuroendocrine tumour (NET)

Status:

Closed

Phase:

Phase 4

This study is to find out more about the drug everolimus (also known Afinitor) as a treatment for neuroendocrine tumours of the pancreas.

Neuroendocrine tumours (NETs) are a rare group of cancers that make and release hormones. They are normally found in the digestive system Open a glossary item . This trial is looking at neuroendocrine tumours of the pancreas.

Doctors may treat neuroendocrine tumours of the pancreas with a drug called everolimus. It is a type of biological therapy. It stops a protein called mTOR from working properly which can help to stop cancer growing.

We know that everolimus can help people who have pancreatic neuroendocrine tumours that can’t be removed with surgery, or have spread to another part of the body. In this study, researchers want to

Learn more about how everolimus affects people’s quality of life
See how well it works in the long term for pancreatic neuroendocrine tumours

Who can enter

You may be able to join this study if all of the following apply

You have a neuroendocrine tumour of the pancreas that can’t be removed with surgery, or has spread to another part of your body
A scan shows that your cancer is getting worse
You are going to start taking everolimus
If you take drugs called somatostatin analogues to control symptoms, you must have been on a stable dose for at least 2 months
You are at least 18 years old

You cannot join this study if you can’t take everolimus for some reason (your doctor can advise you about this).

Trial design

This phase 4 trial will recruit up to 40 people. Everybody taking part has everolimus.

The study team will collect information from your routine hospital appointments and tests for the first 3 years you take everolimus. If you stop taking everolimus during that time, they will collect information for a month after you stop the treatment.

They will also ask you to fill out some questionnaires before you start treatment, each time you go to hospital in the first 6 months, and a month after you stop taking everolimus (if this happens within the first 3 years).

The questionnaires will ask about side effects and how you’ve been feeling. This is called a quality of life study.

You complete the questionnaires on a computer at the hospital. A member of the study team will help you with using the computer.